RayKnowChina Research Map
Shortlist

JinanShandong First Medical University

First Affiliated Hospital of Shandong First Medical University

山东第一医科大学第一附属医院(山东省千佛山医院)

Listed for 22 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at First Affiliated Hospital of Shandong First Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌6 papers led
  2. Hepatocellular carcinoma肝细胞癌32 papers led
  3. Stomach cancer胃癌26 papers led
  4. Hepatoblastoma肝母细胞瘤1 paper led
  5. Retinoblastoma视网膜母细胞瘤0 papers led
  6. Osteosarcoma骨肉瘤3 papers led
  7. Neuroblastoma神经母细胞瘤1 paper led
  8. Multiple myeloma多发性骨髓瘤2 papers led
  9. Haemophilia A血友病 A2 papers led
  10. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  11. Myasthenia gravis重症肌无力11 papers led
  12. Moyamoya disease烟雾病3 papers led
  13. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎4 papers led
  14. Takayasu arteritis大动脉炎1 paper led
  15. Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led
  16. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病1 paper led
  17. Amyotrophic lateral sclerosis肌萎缩侧索硬化症2 papers led
  18. Fabry disease法布雷病1 paper led
  19. IgA nephropathyIgA 肾病1 paper led
  20. Gaucher disease戈谢病0 papers led
  21. Osteogenesis imperfecta成骨不全症1 paper led
  22. Hereditary angioedema遗传性血管性水肿0 papers led

Not listed for: Nasopharyngeal carcinoma, Chordoma, Gastrointestinal stromal tumour, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Wilson disease, Biliary atresia, Hepatic echinococcosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Niemann–Pick disease type C, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 6 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 0020242025: 222025

6 hospitals in Jinan for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunotherapyNeoadjuvant & combined treatmentMolecular markers & genomics
Departments in papersMedical oncologyGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)
Papers it led6
  1. Efficacy and safety of postoperative radiotherapy in locally advanced esophageal squamous cell carcinoma patients with pathologic incomplete response after neoadjuvant immunochemotherapy: a retrospective cohort study.2025Frontiers in immunologyFree full text
  2. The efficacy and safety of adjuvant immunotherapy after neoadjuvant immunotherapy combined with chemotherapy in locally advanced resectable esophageal squamous cell carcinoma: a real-world study.2025Frontiers in immunologyFree full text
  3. RNF106 aggravates esophageal squamous cell carcinoma progression through LATS2/YAP axis.2023Archives of biochemistry and biophysics
  4. Immune checkpoint inhibitor induced colitis and arthritis: A case report.2023MedicineFree full text
  5. Clinicopathological and Prognostic Significance of SMYD3 in Human Cancers: A Systematic Review and Meta-analysis.2022Genetic testing and molecular biomarkers
  6. Upregulation of miR-1269 Contributes to the Progression of Esophageal Squamous Cell Cancer Cells and Is Associated With Poor Prognosis.2021Technology in cancer research & treatmentFree full text
All its trials on ClinicalTrials.gov, any status3
  1. A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCCTerminatedNCT02721550Study sitePhase 4Start 2016-08
  2. A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCCTerminatedNCT02721576Study sitePhase 4Start 2016-07
  3. A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCCCompletedNCT02721563Study sitePhase 4Start 2016-02
More papers found outside PubMed (not counted)8
  1. Adjuvant therapy after neoadjuvant immunotherapy combined with chemotherapy in locally advanced resectable esophageal squamous cell carcinoma: A retrospective study study.2025Journal of Clinical Oncologyarticle
  2. Failure patterns and the value of postoperative adjuvant radiotherapy in esophageal squamous cell carcinoma patients treated with neoadjuvant immunotherapy combined with chemotherapy.2025Journal of Clinical Oncologyarticle
  3. The efficacy and safety of adjuvant immunotherapy after neoadjuvant immunotherapy combined with chemotherapy in locally advanced resectable esophageal squamous cell carcinoma: A real-world study.2025Journal of Clinical Oncologyarticle
  4. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  5. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  6. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  7. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  8. Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF12022Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 32 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
32
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 6620222023: 111120232024: 6620242025: 442025

6 hospitals in Jinan for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicinePathology / laboratory medicineMedical oncology
Papers it led32
  1. Radiomic Model Based on Multisequence MRI to Preoperative Predict Ki-67 Expression in Hepatocellular Carcinoma.2026Academic radiology
  2. Lightweight Spectral-MLP for Hyperspectral Differentiation of Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.2026Journal of biophotonics
  3. Efficacy and safety analysis of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors with or without microwave ablation for unresectable hepatocellular carcinoma: a retrospective, multice2025Frontiers in immunologyFree full text
  4. Comparative diagnostic efficacy of 18F-FDG and FAPI PET/CT in primary liver cancers: A systematic review and meta-analysis.2025Journal of cancer research and therapeutics
  5. Characterization of T-Cell Receptor Profiles Predicts Survival Situation in Patients with Hepatocellular Carcinoma.2025Technology in cancer research & treatmentFree full text
  6. Phthalate exposure and hepatocellular carcinoma: Unraveling mechanisms through network toxicology.2025Toxicology
  7. A Meta-Analysis of MiRNA-497 and Prognosis of Hepatocellular Carcinoma.2024Canadian journal of gastroenterology & hepatologyFree full text
  8. Clinical outcomes of percutaneous microwave ablation for pulmonary oligometastases from hepatocellular carcinoma: a retrospective, multicenter study.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  9. Is intravoxel incoherent motion magnetic resonance imaging useful for predicting hepatocellular cancer recurrence and invasion of the peritumoral zone after transarterial chemoembolization?2024Journal of cancer research and therapeutics
  10. Exosome-derived circUPF2 enhances resistance to targeted therapy by redeploying ferroptosis sensitivity in hepatocellular carcinoma.2024Journal of nanobiotechnologyFree full text
  11. Camptothecin enhances the anti-tumor effect of low-dose apatinib combined with PD-1 inhibitor on hepatocellular carcinoma.2024Scientific reportsFree full text
  12. High throughput sequencing reveals alterations in B cell receptor repertoires associated with the progression of hepatic cirrhosis to hepatocellular carcinoma.2024Tumori
  13. The lipid peroxidation-derived DNA adduct γ-OHPdG as a diagnostic and prognostic biomarker in hepatocellular carcinoma.2023AgingFree full text
  14. circFAM134B is a key factor regulating reticulophagy-mediated ferroptosis in hepatocellular carcinoma.2023Cell cycle (Georgetown, Tex.)Free full text
  15. Exosomal circTGFBR2 promotes hepatocellular carcinoma progression via enhancing ATG5 mediated protective autophagy.2023Cell death & diseaseFree full text
  16. ZNF8-miR-552-5p Axis Modulates ACSL4-Mediated Ferroptosis in Hepatocellular Carcinoma.2023DNA and cell biology
  17. Iron accumulation and lipid peroxidation: implication of ferroptosis in hepatocellular carcinoma.2023Frontiers in endocrinologyFree full text
  18. Clinical and prognostic significance of CCPG1 in hepatocellular carcinoma.2023General physiology and biophysics
  19. Significant response to transarterial chemoembolization combined with PD-1 inhibitor and apatinib for advanced intrahepatic cholangiocarcinoma: A case report and literature review.2023Journal of cancer research and therapeutics
  20. Transmembrane protein 147, as a potential Sorafenib target, could expedite cell cycle process and confer adverse prognosis in hepatocellular carcinoma.2023Molecular carcinogenesis
  21. Camptothecin improves sorafenib sensitivity by inhibiting Nrf2‑ARE pathway in hepatocellular carcinoma.2023Oncology reportsFree full text
  22. DNA damage repair-related gene signature for identifying the immune status and predicting the prognosis of hepatocellular carcinoma.2023Scientific reportsFree full text
  23. Laparoscopic versus open surgery for hepatic caudate lobectomy: a retrospective study.2023Surgical endoscopy
  24. Natural history of decompensated cirrhosis with serum hepatitis B DNA < 2000 IU/mL: a retrospective study.2022BMC gastroenterologyFree full text
  25. Targeting FAM134B-mediated reticulophagy activates sorafenib-induced ferroptosis in hepatocellular carcinoma.2022Biochemical and biophysical research communications
  26. IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma.2022Biochemical and biophysical research communications
  27. Depleting circ_0088364 restrained cell growth and motility of human hepatocellular carcinoma via circ_0088364-miR-1270-COL4A1 ceRNA pathway.2022Cell cycle (Georgetown, Tex.)Free full text
  28. The deubiquitinase USP7 regulates oxidative stress through stabilization of HO-1.2022Oncogene
  29. Highly expressed FAM189B predicts poor prognosis in hepatocellular carcinoma.2022Pathology oncology research : PORFree full text
  30. RNA binding protein DAZAP1 promotes HCC progression and regulates ferroptosis by interacting with SLC7A11 mRNA.2021Experimental cell research
  31. Determination of risk factors for fever after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.2021MedicineFree full text
  32. The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma.2021Scientific reportsFree full text
All its trials on ClinicalTrials.gov, any status3
  1. A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.Status unknownNCT06205732Lead sponsorStart 2024-01
  2. Study on the Efficacy and Safety of Conversion Therapy in Patients With Initially Unresectable Hepatocellular CarcinomaStatus unknownNCT06365034Lead sponsorStart 2024-03
  3. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Study sitePhase 3Start 2019-12

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 26 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
26
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 6620232024: 101020242025: 332025

7 hospitals in Jinan for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  2. Recruiting
    The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
    Phase
    N/A
    Started
    2023-12
    Registry
    NCT06081647

    Age 18 years to 60 years (registered criteria)

    Led by Renji Hospital; 7 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Nanjing, Shanghai

  3. Enrolling by invitation
    An Artificial Intelligence Model for Aiding Claudin18.2 Expression Diagnosis in Gastric Adenocarcinoma
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07274579

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang Hospital; 1 listed hospital as study siteGuangzhou, Jinan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapy & targeted drugsChemotherapy & combined treatmentImaging & AI
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyPathology / laboratory medicineGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led26
  1. Nanozymes induced Z-scheme Mn-BiVO4/Au/Bi2S3 heterostructure photoelectrochemical signal amplification for CA72-4 detection.2026Biosensors & bioelectronics
  2. Targeting drug-tolerant persister cells to overcome resistance in HER2-positive gastric cancer.2026Critical reviews in oncology/hematology
  3. Mendelian Randomization and Transcriptome Data Analysis Reveal Bidirectional Causal Relationships and Mechanisms between Type 2 Diabetes and Gastric Cancer.2025Current medicinal chemistry
  4. Analysis of shared pathogenic mechanisms and drug targets in myocardial infarction and gastric cancer based on transcriptomics and machine learning.2025Frontiers in immunologyFree full text
  5. Exploring the regulatory mechanisms of paraptosis-related prognostic genes in gastric cancer using single-cell sequencing and transcriptome analysis.2025Scientific reportsFree full text
  6. Neoadjuvant immunotherapy improves outcomes for resectable gastroesophageal junction cancer: A systematic review and meta-analysis.2024Cancer medicineFree full text
  7. Circular RNA Circ_0001322 inhibits gastric cancer progression by modulating the miR-1264/QKI axis and suppressing the Hedgehog pathway.2024Cellular and molecular biology (Noisy-le-Grand, France)
  8. Nomogram for predicting overall survival after curative gastrectomy using inflammatory, nutritional and pathological factors.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  9. Gentiopicroside inhibits the progression of gastric cancer through modulating EGFR/PI3K/AKT signaling pathway.2024European journal of medical researchFree full text
  10. Hepatoid adenocarcinoma of the stomach with ideal response to neoadjuvant chemo-immunotherapy: a case report.2024Frontiers in immunologyFree full text
  11. Prognostic relevance of prognostic nutritional indices in gastric or gastro-esophageal junction cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.2024Frontiers in immunologyFree full text
  12. Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification : Immunoneoadjuvant therapy of gastric cancer.2024Investigational new drugs
  13. Efficacy and safety of neoadjuvant therapy in gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.2024Journal of cancer research and therapeutics
  14. The E3 ligase TRIM7 suppresses the tumorigenesis of gastric cancer by targeting SLC7A11.2024Scientific reportsFree full text
  15. Bile acids inhibit ferroptosis sensitivity through activating farnesoid X receptor in gastric cancer cells.2024World journal of gastroenterologyFree full text
  16. DSC2 suppresses the growth of gastric cancer through the inhibition of nuclear translocation of γ-catenin and PTEN/PI3K/AKT signaling pathway.2023AgingFree full text
  17. A Novel Scoring System in Predicting Prognosis After Adjuvant FOLFOX Chemotherapy in Gastric Cancer.2023Cancer biotherapy & radiopharmaceuticals
  18. circSLC4A7 accelerates stemness and progression of gastric cancer by interacting with HSP90 to activate NOTCH1 signaling pathway.2023Cell death & diseaseFree full text
  19. Microdissection of cancer-associated fibroblast infiltration subtypes unveils the secreted SERPINE2 contributing to immunosuppressive microenvironment and immuotherapeutic resistance in gastric cancer: A large-scale study integrating bulk a2023Computers in biology and medicine
  20. Pseudoprogression during immunotherapy for gastric adenocarcinoma: A case report and literature review.2023Journal of cancer research and therapeutics
  21. Huntingtin-associated protein 1 is a potential tumor suppressor for gastric cancer.2023Molecular biology reports
  22. PADI4 promotes epithelial-mesenchymal transition(EMT) in gastric cancer via the upregulation of interleukin 8.2022BMC gastroenterologyFree full text
  23. PRDX3 promotes resistance to cisplatin in gastric cancer cells.2022Journal of cancer research and therapeutics
  24. Investigating the effect of ARHGEF10L gene on tumor growth in gastric cancer in a nude mouse model using quantitative MRI parameters.2022Journal of cancer research and therapeutics
  25. MicroRNAs are involved in the development and progression of gastric cancer.2021Acta pharmacologica SinicaFree full text
  26. Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study.2021The British journal of radiologyRCTFree full text
All its trials on ClinicalTrials.gov, any status6
  1. Effect of Precise Grip Strength Training on PICC Catheter-Related Thrombosis in Cancer PatientsCompletedNCT05638048Lead (inferred)N/AStart 2022-07
  2. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  3. An Artificial Intelligence Model for Aiding Claudin18.2 Expression Diagnosis in Gastric AdenocarcinomaEnrolling by invitationNCT07274579Study siteStart 2025-10
  4. The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy ProcedureRecruitingNCT06081647Study siteN/AStart 2023-12
  5. First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric CancerActive, not recruitingNCT05586061Study sitePhase 2Start 2023-02
  6. Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior ImmunotherapyActive, not recruitingNCT05585580Study sitePhase 2Start 2023-03

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

4 hospitals in Jinan for hepatoblastoma86 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led1
  1. SOX7 modulates the progression of hepatoblastoma through the regulation of Wnt/β-catenin signaling pathway.2022Journal of cancer research and therapeutics
All its trials on ClinicalTrials.gov, any status1
  1. G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant TumorStatus unknownNCT02933333Study sitePhase 4Start 2016-09

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Jinan for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 3 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 112025

18 hospitals in Jinan for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

8 hospitals in Jinan for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led1
  1. FTO inhibits oxidative stress by mediating m6A demethylation of Nrf2 to alleviate cerebral ischemia/reperfusion injury.2023Journal of physiology and biochemistry
Earlier papers (2016–2020)1
  1. MiR-424 suppressed viability and invasion by targeting to the DCLK1 in neuroblastoma.2020European review for medical and pharmacological sciences
All its trials on ClinicalTrials.gov, any status1
  1. G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant TumorStatus unknownNCT02933333Study sitePhase 4Start 2016-09

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 2 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.1%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

7 hospitals in Jinan for multiple myeloma175 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 2 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Jinan for haemophilia A132 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Jinan for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 11 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 2.2%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 1120232024: 1120242025: 442025

4 hospitals in Jinan for myasthenia gravis89 hospitals in China for myasthenia gravis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06447597

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Wuhan, Xi'an, Zunyi

  2. Recruiting
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    Phase
    Phase 3
    Started
    2021-07
    Registry
    NCT04951622

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesCrisis & intensive careAntibodies & diagnosisThymus & thymectomy
Departments in papersNeurology

Over half of these papers are lab or animal studies.

Papers it led11
  1. Phenotypic and functional dysregulations of CD8 + T Cells in myasthenia gravis.2025Clinical and experimental medicineFree full text
  2. Myasthenia gravis with double-seropositive acetylcholine receptor and low-density lipoprotein receptor-related protein 4 antibodies combined with muscle atrophy: a case report and literature review.2025Frontiers in immunologyFree full text
  3. Resveratrol-A Herbal Immunomodulator, Ameliorates Experimental Autoimmune Myasthenia Gravis by Regulating the Foxo1-Foxp3 Pathway.2025Journal of biochemical and molecular toxicology
  4. Diabetes exacerbates myasthenia gravis by enhancing pathological thymic output via the GPR183-7α,25-OHC axis.2025Journal of neuroinflammationFree full text
  5. Dihydroartemisinin ameliorates experimental autoimmune myasthenia gravis by regulating CD4+ T cells and modulating gut microbiota.2024International immunopharmacology
  6. Extracellular vesicles encapsulated with caspase-1 inhibitor ameliorate experimental autoimmune myasthenia gravis through targeting macrophages.2023Journal of controlled release : official journal of the Controlled Release Society
  7. Myasthenia gravis: The pharmacological basis of traditional Chinese medicine for its clinical application.2022BioFactors (Oxford, England)
  8. Diabetes mellitus aggravates humoral immune response in myasthenia gravis by promoting differentiation and activation of circulating Tfh cells.2022Clinical immunology (Orlando, Fla.)
  9. Natural killer cells promote the differentiation of follicular helper T cells instead of inducing apoptosis in myasthenia gravis.2021International immunopharmacology
  10. Prophylactic administration of fingolimod (FTY720) ameliorated experimental autoimmune myasthenia gravis by reducing the number of dendritic cells, follicular T helper cells and antibody-secreting cells.2021International immunopharmacology
  11. Diabetes mellitus exacerbates experimental autoimmune myasthenia gravis via modulating both adaptive and innate immunity.2021Journal of neuroinflammationFree full text
All its trials on ClinicalTrials.gov, any status3
  1. A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.RecruitingNCT06447597Study sitePhase 2/Phase 3Start 2024-07
  2. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisRecruitingNCT04951622Study sitePhase 3Start 2021-07
  3. A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia GravisTerminatedNCT04963270Study sitePhase 3Start 2021-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 3 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 112025

1 hospital in Jinan for moyamoya disease47 hospitals in China for moyamoya disease

No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & blood flowRevascularisation surgeryGenetics
Departments in papersRadiology / nuclear medicinePathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 4 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 1.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 0020232024: 0020242025: 002025

5 hospitals in Jinan for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyNeurosurgery
Papers it led4
  1. Increased formation of neutrophil extracellular traps in patients with anti-N-methyl-d-aspartate receptor encephalitis.2022Frontiers in immunology
  2. Coexistence of NMDAR, GAD65, and SOX1 antibody-associated autoimmune encephalitis.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  3. Recurrent anti-AMPA receptor encephalitis associated with thymus cancer.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  4. Long-term follow-up of a child with anti-AMPA receptor encephalitis.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Jinan for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

8 hospitals in Jinan for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status3
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. A Phase I Study of HW241045 in Healthy SubjectsNot yet recruitingNCT07593690Study sitePhase 1Start 2026-06
  3. A Trial of SHR - 1906 in Healthy SubjectsCompletedNCT04986540Study sitePhase 1Start 2021-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led 1 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 2.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Jinan for lymphangioleiomyomatosis27 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Tuberous sclerosis complex associated lymphangioleiomyomatosis.2023QJM : monthly journal of the Association of Physicians

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 2 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

8 hospitals in Jinan for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Jinan for Fabry disease80 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

9 hospitals in Jinan for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Papers it led1
  1. BAFF in autoimmune kidney diseases: pathogenic pathways, biomarker potential, and therapeutic horizons.2025Renal failure
Earlier papers (2016–2020)1
  1. Increasing prevalence of membranous nephropathy in patients with primary glomerular diseases: A cross-sectional study in China.2017Nephrology (Carlton, Vic.)
All its trials on ClinicalTrials.gov, any status3
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  2. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  3. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Jinan for Gaucher disease40 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Jinan for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hereditary angioedema

遗传性血管性水肿

Led no English-language PubMed papers on hereditary angioedema in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Jinan for hereditary angioedema30 hospitals in China for hereditary angioedema

No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in ChinaCompletedNCT06346899Study siteStart 2024-07

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

山东第一医科大学第一附属医院(山东省千佛山医院)

First Affiliated Hospital of Shandong First Medical University

济南

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Shandong Provincial Qianfoshan Hospital; Qianfoshan Hospital Affiliated to Shandong University; Qianfoshan Hospital; Shandong Qianfoshan Hospital; Qianfoshan Hospital Affiliated with Shandong University; Shandong Qianfoshan Hospital Affiliated With Shandong University; Shandong Qianfoshan Hospital Affiliated to Shandong University; first affiliated hospital of Shandong First medical university

Suggest a correctionDownload the data